The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor
Feng, Y., Broder, C. C., Kennedy, P. E., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5263.872 · Cited by 4,172
Zlotnik, A., & Yoshie, O. (2000) · Immunity · doi:10.1016/s1074-7613(00)80165-x · Cited by 3,859
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Chemokines and leukocyte traffic
Baggiolini, M. (1998) · Nature · doi:10.1038/33340 · Cited by 2,709
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development
Zou, Y.-R., Kottmann, A. H., Kuroda, M., Taniuchi, I., & Littman, D. R. (1998) · Nature · doi:10.1038/31269 · Cited by 2,489
Sugiyama, T., Kohara, H., Noda, M., & Nagasawa, T. (2006) · Immunity · doi:10.1016/j.immuni.2006.10.016 · Cited by 2,412
Cited by
Bissell, M. J., & Hines, W. C. (2011) · Nature Medicine · doi:10.1038/nm.2328 · Cited by 1,517
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Teicher, B. A., & Fricker, S. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2329 · Cited by 1,449
Herishanu, Y., Pérez-Galán, P., Liu, D., Biancotto, A., Pittaluga, S., Vire, B., Gibellini, F., Njuguna, N., Lee, E., Stennett, L., et al. (2011) · Blood · doi:10.1182/blood-2010-05-284984 · Cited by 815
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
“Antagonists of CXCR4 can disrupt these interactions, forcing the leukemia cells back into circulation where they are more susceptible to chemotherapeutic drugs [122], and may serve as crucial additions on nanodrugs.”
BackgroundCancer stem cell definitions and terminology: the devil is in the details
Valent, P., Bonnet, D., De Maria, R., Lapidot, T., Copland, M., Melo, J. V., Chomienne, C., Ishikawa, F., Schuringa, J. J., Stassi, G., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3368 · Cited by 692
The Intricate Role of CXCR4 in Cancer
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-411638-2.00002-1 · Cited by 672
A review on CXCR4/CXCL12 axis in oncology: No place to hide
Domanska, U. M., Kruizinga, R. C., Nagengast, W. B., Timmer-Bosscha, H., Huls, G., de Vries, E. G. E., & Walenkamp, A. M. E. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.005 · Cited by 635
Understanding and targeting cancer stem cells: therapeutic implications and challenges
Chen, K., Huang, Y.-H., & Chen, J.-L. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.27 · Cited by 608
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Burger, J. A., Ghia, P., Rosenwald, A., & Caligaris-Cappio, F. (2009) · Blood · doi:10.1182/blood-2009-06-225326 · Cited by 577
Self-citationNanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
Shi, Y., Riese, D. J., & Shen, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.574667 · Cited by 336
Jenq, R. R., & van den Brink, M. R. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2804 · Cited by 299
Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment
Scala, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0914 · Cited by 290
Burger, J. A., & Gribben, J. G. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.08.011 · Cited by 285
Self-citationHerrmann, K., Schottelius, M., Lapa, C., Osl, T., Poschenrieder, A., Hänscheid, H., Lückerath, K., Schreder, M., Bluemel, C., Knott, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167361 · Cited by 276
Unraveling the Role of Angiogenesis in Cancer Ecosystems
Zuazo-Gaztelu, I., & Casanovas, O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00248 · Cited by 275
Contribution of bone microenvironment to leukemogenesis and leukemia progression
Ayala, F., Dewar, R., Kieran, M., & Kalluri, R. (2009) · Leukemia · doi:10.1038/leu.2009.175 · Cited by 273
The cancer stem cell niche—there goes the neighborhood?
Cabarcas, S. M., Mathews, L. A., & Farrar, W. L. (2011) · International Journal of Cancer · doi:10.1002/ijc.26312 · Cited by 265
Abraham, M., Klein, S., Bulvik, B., Wald, H., Weiss, I. D., Olam, D., Weiss, L., Beider, K., Eizenberg, O., Wald, O., et al. (2017) · Leukemia · doi:10.1038/leu.2017.82 · Cited by 104
Self-citation
Metadata
- Authors
- Burger, J. A., & Peled, A.
- Venue
- Leukemia
- Published
- 2008-11-06
- Volume
- 23
- Issue
- 1
- Pages
- 43-52
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2149888039
- Cited by
- 462
- References
- 133
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.